SCHEMBL144726

SCHEMBL144726

N=C(N)NCCCN[C@@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 2/20 0.40
C3AR1 Q16581 1/20 0.39
NOD1 Q9Y239 2/20 0.38
ALOX15 P16050 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.36
ITGB3 P05106 1/20 0.35
ITGA2B P08514 1/20 0.35
FOLH1 Q04609 2/20 0.35
OTC P00480 1/20 0.34
NPY4R P50391 4/20 0.33
NPY1R P25929 3/20 0.33
NPY2R P49146 3/20 0.33
NPY5R Q15761 3/20 0.33
DDAH1 O94760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149706 0.95 NOD1 (0.43) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL28573558 0.92 GGT1 (0.37) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL3897621 0.92 GGT1 (0.37) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL1343491 0.91 NOD1 (0.49) GGT1C3AR1NOD1ALOX15FOLH1
SCHEMBL6698785 0.91 GGT1 (0.43) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL6429710 0.91 NOD1 (0.49) GGT1C3AR1NOD1ALOX15FOLH1
Water SCHEMBL28277856 0.91 GGT1 (0.36) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL6698783 0.91 GGT1 (0.43) GGT1C3AR1NOD1ALOX15MEN1
Hydrochloric Acid SCHEMBL22466335 0.91 GGT1 (0.36) GGT1C3AR1NOD1ALOX15MEN1
SCHEMBL13060031 0.90 GGT1 (0.38) GGT1C3AR1NOD1ALOX15MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US claimed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO claimed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP claimed
CN-117098544-A Diterpenoid compounds acting on Protein Kinase C (PKC) K-GEN治疗股份有限公司 2023-11-21 CN claimed
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. 2022-12-29 US claimed
WO-2022204327-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN, INC. (US) 2022-09-29 WO claimed
EP-4041268-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen, Inc. (US) 2022-08-17 EP claimed
CN-114786697-A Diterpenoids acting on Protein Kinase C (PKC) K-GEN股份有限公司 2022-07-22 CN claimed
WO-2011147881-A2 CYCLIC DIPEPTIDES AS FEEDSTUFF ADDITIVES EVONIK DEGUSSA GMBH (DE) 2011-12-01 WO claimed
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES VICTORIA LINK LIMITED (NZ) 2024-08-29 US disclosed
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-GEN THERAPEUTICS, INC. (US) 2024-06-20 US disclosed
EP-4351581-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES Victoria Link Limited (NZ) 2024-04-17 EP disclosed
WO-2024064391-A2 USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT K-GEN THERAPEUTICS, INC. (US) 2024-03-28 WO disclosed
EP-4313095-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) K-Gen Therapeutics, Inc. (US) 2024-02-07 EP disclosed
US-7883713-B2 Suspension, ointment, solution, spray, lotion, gel, cream, powder, powder spray, paste, emulsion, foam or stick; for treatment of herpes infections in humans AICURIS GMBH & CO. KG (DE) 2011-02-08 US disclosed
US-20100273789-A1 AMINOACYL PRODRUGS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-28 US disclosed
US-7230017-B2 Dihydropyridinone derivatives BAYER HEALTHCARE AG (DE) 2007-06-12 US disclosed
US-20060100207-A1 Dihydropyridinone derivatives BAYER HEALTHCARE AG (DE) 2006-05-11 US disclosed
EP-0934260-A1 N ALPHA-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS Hyundai Pharm. Ind. Co., Ltd. (KR) 1999-08-11 EP disclosed
WO-1998017638-A1 Nα-2-(4-NITROPHENYLSULFONYL)ETHOXYCARBONYL-AMINO ACIDS HYUNDAI PHARM. IND. CO., LTD. (KR) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100207-A1 Dihydropyridinone derivatives TNNI3, DHPS, TNNT2 GGT1 1685/4885C3AR1 2258/4885NOD1 2884/4885
US-20240287123-A1 ANTIVIRAL NUCLEOSIDE ANALOGUES EBNA1BP2, RPL35, RPL7 GGT1 811/4885C3AR1 2300/4885NOD1 1665/4885
US-20100273789-A1 AMINOACYL PRODRUGS AADAC, DNPEP, AADAT GGT1 929/4885C3AR1 2686/4885NOD1 1160/4885
US-20220411362-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCH, PRKCB GGT1 652/4885C3AR1 4116/4885NOD1 4702/4885
US-20240197666-A1 DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) PRKCA, PRKCB, PRKCI GGT1 887/4885C3AR1 1792/4885NOD1 3039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.